Calcilytics: antagonists of the calcium-sensing receptor for the treatment of osteoporosis

Papers of special note have been highlighted as: ▪ of interest ▪▪ of considerable interest

Bibliography

• 1  Berry SD, Kiel DP, Donaldson MG et al. Application of the National Osteoporosis Foundation guidelines to postmenopausal women and men: the Framingham osteoporosis study. Osteoporosis Int.21,53–60 (2010).
  Medline CASGoogle Scholar
• 2  Ray NF, Chan JK, Thamer M, Melton LJ. Fractures attributable to osteoporosis: report from the National Osteoporosis Foundation. J. Bone Miner. Res.12,24–35 (1997).
  Medline CASGoogle Scholar
• 3  Tarantino U, Cannata G, Lecce D, Celi M, Cerocchi I, Lundusi R. Incidence of fragility fractures. Aging Clin. Exp. Res.19(Suppl. 4),7–11 (2007).
  MedlineGoogle Scholar
• 4  Jilka RL. Molecular and cellular mechanisms of the anabolic effect of intermittent PTH. Bone40,1434–1446 (2007).
  Medline CASGoogle Scholar
• 5  Russell RG, Espina B, Hulley P. Bone biology and the pathogenesis of osteoporosis. Curr. Opin. Rheumatol.18(Suppl. 1),S3–S10 (2006).
  MedlineGoogle Scholar
• 6  Canalis E, Giustina A, Bilezikian JP. Mechanisms of anabolic therapies for osteoporosis. N. Engl. J. Med.357,905–916 (2007).
  Medline CASGoogle Scholar
• 7  Martin TJ, Sims NA. Osteoclast-derived activity in the coupling of bone formation to resorption. Trends Mol. Med.11,76–81 (2005).
  Medline CASGoogle Scholar
• 8  Neer RM, Arnaud DC, Zanchetta JR et al. Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N. Engl. J. Med.344,1434–1341 (2001).
  Medline CASGoogle Scholar
• 9  File E, Deal D. Clinical update on teriparatide. Curr. Rheumatol. Reports11,169–176 (2009).
  Medline CASGoogle Scholar
• 10  Blick SK, Dhillon S, Keam SJ. Teriparatide: a review of its use in osteoporosis. Drugs68,2709–2737 (2008).
  Medline CASGoogle Scholar
• 11  Stroup J, Kane MP, Abu-Baker AM. Teriparatide in the treatment of osteoporosis. Am. J. Health Syst. Pharm.65,532–539 (2008).
  Medline CASGoogle Scholar
• 12  Horowitz MJ, Tedesco MB, Gundberg C, Garcia-Ocana A, Stewart AF. Short-term, high-dose parathyroid hormone-related protein as a skeletal anabolic agent for the treatment of postmenopausal osteoporosis. J. Clin. Endocrinol. Metab.88,569–575 (2003).
  MedlineGoogle Scholar
• 13  O’Dea L, Lyttle CR, Rosen CJ. BA058, a novel analog of human parathyroid hormone-related peptide (PTHrP), induces evidence of bone formation without evidence of bone resorption over 7 days of exposure. Presented at: The 89^th Annual Meeting of the Endocrine Society, Abstract P2–137. Toronto, ON, Canada, 2–5 June 2007.
  Google Scholar
• 14  Fox J. Developments in parathyroid hormone and related peptides as bone-formation agents. Curr. Opin. Pharmacol.2,338–344 (2002).
  Medline CASGoogle Scholar
• 15  Morley P. Delivery of parathyroid hormone for the treatment of osteoporosis. Expert Opin. Drug Deliv.2,993–1002 (2005).
  Medline CASGoogle Scholar
• 16  Tashjian AH, Goltzman D. On the interpretation of rat carcinogenicity studies for human PTH(1–34) and human PTH(1–84). J. Bone Miner. Res.23,803–811 (2008).
  Medline CASGoogle Scholar
• 17  Trivedi R, Mitah A, Chattopadhyay N. Recent updates on the calcium-sensing receptor as a drug target. Curr. Med. Chem.15,178–186 (2008).
  Medline CASGoogle Scholar
• 18  Brown EM. The calcium-sensing receptor: physiology, pathophysiology and CaR-based therapeutics. Subcell. Biochem.45,139–165 (2007).▪ Comprehensive review of biology, disorders and therapeutics based on the calcium-sensing receptor.
  Medline CASGoogle Scholar
• 19  Dempster DW, Cosman F, Parisien M, Shen V, Lindsay R. Anabolic actions of parathyroid hormone on bone. Endocrine Rev.14,690–709 (1993).
  Medline CASGoogle Scholar
• 20  Qin L, Raggatt LJ, Partridge NC. Parathyroid hormone: a double-edged sword for bone metabolism. Trends Endocrinol. Metab.15,60–65 (2004).▪ Effect of parathyroid hormone on bone: anabolic or catabolic action depending on exposure time.
  Medline CASGoogle Scholar
• 21  Loitnun S, Sibonga J, Turner R. Differential effects of intermittent and continuous administration of parathyroid hormone on bone histomorphometry and gene expression. Endocrine17,29–36 (2002).
  MedlineGoogle Scholar
• 22  Frolik CA, Black EC, Cain RL et al. Anabolic and catabolic effects of human parathyroid hormone (1–34) are predicted by duration of hormone exposure. Bone33,372–379 (2003).
  Medline CASGoogle Scholar
• 23  Kramer I, Keller H, Leupin O, Kneissel M. Does osteocytic SOST suppression mediate PTH bone anabolism? Trends Endocrinol. Metab.21,237–244 (2010).
  Medline CASGoogle Scholar
• 24  Goltzman D. Studies on the mechanisms of the skeletal anabolic action of endogenous and exogenous parathyroid hormone. Arch. Biochem. Biophys.473,218–224 (2008).
  Medline CASGoogle Scholar
• 25  Poole KE, Reeve J. Parathyroid hormone – a bone anabolic and catabolic agent. Curr. Opin. Pharmacol.5,612–617 (2005).
  Medline CASGoogle Scholar
• 26  Messa P, Alfieri C, Brezzi B. Cinacalcet: pharmacological and clinical aspects. Expert Opin. Drug Metabol. Toxicol.4,1551–1560 (2008).
  Medline CASGoogle Scholar
• 27  Harrington P, Fotsch C. Calcium sensing receptor activators: calcimimetics. Curr. Med. Chem.14,3027–3034 (2007).
  Medline CASGoogle Scholar
• 28  Nemeth EF. The search for calcium receptor antagonists (calcilytics). J. Mol. Endocrinol.29,15–21 (2002).
  Medline CASGoogle Scholar
• 29  Nemeth EF. Anabolic therapy for osteoporosis: calcilytics. Bonekey Osteovision5(6),196–208 (2008).▪▪ Brief review of calcilytics: concept, molecular structures and clinical results.
  Google Scholar
• 30  Nemeth EF. Drugs acting on the calcium receptor. In: Principles of Bone Biology (3^rd Edition). Bilezikian JP, Raisz LG, Martin TJ (Eds). Elsevier, San Diego, CA, USA 1711–1735 (2008).
  Google Scholar
• 31  Trivedi R, Mithal A, Chattopadhyay N. Pharmacological manipulation of calcium-sensing receptor: prospect as anabolic therapy for postmenopausal osteoporosis. Drugs Fut.34,803–809 (2009).▪▪ Brief but most comprehensive review of calcilytic compounds.
  CASGoogle Scholar
• 32  Allen JG, Fotsch C, Babij P. Emerging targets in osteoporosis disease modification. J. Med. Chem.53,4332–4353 (2010).
  Medline CASGoogle Scholar
• 33  Marquis RW, Lago AM, Callahan JF et al. Antagonists of the calcium receptor I. Amino alcohol-based parathyroid hormone secretagogues. J. Med. Chem.52,3982–3993 (2009).
  Medline CASGoogle Scholar
• 34  Gowen M, Stroup GB, Dodds RA et al. Antagonizing the parathyroid calcium receptor stimulates parathyroid hormone secretion and bone formation in osteopenic rats. J. Clin. Invest.105,1595–1604 (2000).
  Medline CASGoogle Scholar
• 35  Nemeth EF, Delmar EG, Heaton WL et al. Calcilytic compounds: potent and selective Ca²⁺ receptor antagonists that stimulate secretion of parathyroid hormone. J. Pharmacol. Exp. Ther.299,323–331 (2001).
  Medline CASGoogle Scholar
• 36  Marquis RW, Lago AM, Callahan JF et al. Antagonists of the calcium receptor II. Amino alcohol-based parathyroid hormone secretagogues. J. Med. Chem.52,6599–6605 (2009).▪ Incorporation of a polar carboxylic acid moiety into the amino-alcohol structure significantly improves the selectivity and the pharmacokinetic profile of NPS 2143 (ronacaleret and analogs).
  Medline CASGoogle Scholar
• 37  Kumar S, Matheny CJ, Hoffman SJ et al. An orally active calcium-sensing receptor antagonist that transiently increases plasma concentrations of PTH and stimulates bone formation. Bone46,534–542 (2010).
  Medline CASGoogle Scholar
• 38  Fitzpatrick LA, Brennan E, Kumar S et al. Ronacaleret, a novel calcium-sensing receptor antagonist, demonstrates potential as an oral bone-forming therapy in healthy postmenopausal women. J. Bone Miner. Res.23(Suppl. 50), (2008).
  Google Scholar
• 39  Glover SJ, Eastell R, McCloskey EV et al. Rapid and robust response of biochemical markers of bone formation to teriparatide therapy. Bone45,1053 (2009).
  Medline CASGoogle Scholar
• 40  Lindsay R, Nieves J, Henneman E, Shen V, Cosman F. Subcutaneous administration of the amino-terminal fragment of human parathyroid hormone-(1–34): kinetics and biochemical response in estrogenized oseoporotic patients. J. Clin. Endocrinol. Metab.77,1535–1539 (1993).
  MedlineGoogle Scholar
• 41  Fitzpatrick L, Dabrowski C, Cicconetti G et al. Ronacaleret, a calcium-sensing receptor antagonist: results of a 1 year double-blind, placebo-controlled, dose ranging phase II study. J. Bone Miner. Res.24(Suppl. 1), Abstract 1130 (2009).
  Google Scholar
• 42  Shinagawa Y, Inoue T, Hirata K et al. New aminopropandiol derivatives as orally available and short-acting calcium-sensing receptor antagonists. Bioorg. Med. Chem. Lett.20,3809–3813 (2010).
  Medline CASGoogle Scholar
• 43  Shinagawa Y, Inoue T, Katsushima T et al. Discovery of a potent and short-acting oral calcilytic with a pulsatile secretion of parathyroid hormone. ACS Med. Chem. Lett. DOI: 10.1021/ml100268k (2010) (Epub ahead of print).
  MedlineGoogle Scholar
• 44  Fukumoto S, Nakamura T, Nishizawa Y, Hayashi M, Matsumoto R. JTT-305 shows promise for the treatment of hypocalcemia and osteoporosis. J. Bone Miner. Res.24(Suppl. 1), Abstract 1131 (2009).
  MedlineGoogle Scholar
• 45  Balan G, Bauman J, Bhattacharya S et al. The discovery of novel calcium sensing receptor negative allosteric modulators. Bioorg. Med. Chem.19,3328–3332 (2009).
  CASGoogle Scholar
• 46  Bodor N, Buchwald P. Soft drug design: general principles and recent applications. Med. Res. Rev.20,58–101 (2000).
  Medline CASGoogle Scholar
• 47  Southers JA, Bauman JN, Price DA et al. Metabolism-guided design of short-acting calcium-sensing receptor antagonists. ACS Med. Chem. Lett.1,219–223 (2010).
  CASGoogle Scholar
• 48  Yang W, Wang Y, Roborge JY, Ma Z et al. Discovery and structure–activity relationships of 2-benzlypyrrolidine-substituted aryloxypropanols as calcium-sensing receptor antagonists. Bioorg. Med. Chem. Lett.15,1225–1228 (2005).
  Medline CASGoogle Scholar
• 49  Gavai AV, Vaz RJ, Mikkilineni AB et al. Discovery of novel 1-arylmethylpyrrolidin-2-ylethanolamines as calcium-sensing receptor antagonists. Bioorg. Med. Chem. Lett.15,5478–5482 (2005).
  Medline CASGoogle Scholar
• 50  Kessler A, Faure H, Roussanne MC et al. N¹-arylsulfonyl-N²-(1-(1-naphthyl)ethyl)-1,2-diaminocyclohexanes: a new class of calcilytic agents acting at the calcium-sensing receptor. ChemBioChem4,1131–1136 (2004).
  Google Scholar
• 51  Kessler A, Faure H, Petrel C et al. N¹-Benzoyl-N²-[1-(1-naphthyl)ethyl]-trans-1,2-diaminocyclohexanes: development of 4-chlorophenylcarboxamide (Calhex 231) as a new calcium sensing receptor ligand demonstrating potent calcilytic activity. J. Med. Chem.49,5119–5128 (2006).▪ Structure–activity relationship study leading to Calhex231 at the Centre National de la Recherche Scientifique (CNRS).
  Medline CASGoogle Scholar
• 52  Yang W, Ruan Z, Wang Y et al. Discovery and structure–activity relationships of trisubstituted pyrimidines/pyridines as novel calcium-sensing receptor antagonists. J. Med. Chem.52,1204–1208 (2009).▪ Pyrimidine/pyridine series developed by Bristol-Myers Squibb.
  Medline CASGoogle Scholar
• 53  Arey BJ, Seethala R, Ma Z et al. A novel calcium-sensing receptor antagonist transiently stimulates parathyroid hormone secretion in vivo. Endocrinology146,2015–2022 (2005).
  Medline CASGoogle Scholar
• 54  Shcherbakova I, Balandrin MF, Fox J et al. 3H-quinazolin-4-ones as a new calcilytic template for the potential treatment of osteoporosis. Bioorg. Med. Chem. Lett.15,1557–1560 (2005).
  Medline CASGoogle Scholar
• 55  Kalgutkar AS, Griffith DA, Ryder T et al. Discovery tactics to mitigate toxicity risks due to reactive metabolite formation with 2-(2-hydroxyaryl)-5-(trifluoromehtyl)pyrido[4,3-d]pyrimidin-4(3H)-one derivatives, potent calcium-sensing receptor antagonists and clinical candidate(s) for the treatment of osteoporosis. Chem. Res. Toxicol.23,1115–1126 (2010).
  Medline CASGoogle Scholar
• 56  Shcherbakova I, Huang G, Geoffroy OJ et al. Design, new synthesis, and calcilytic activity of substituted 3H-pyrimidin-4-ones. Bioorg. Med. Chem. Lett.15,2537–2540 (2005).▪ From quinazolin-4-ones to pyrimidinones, a back-up series developed at NPS Pharmaceuticals.
  Medline CASGoogle Scholar
• 57  Didiuk MT, Griffith DA, Benbow JW et al. Short-acting 5-(trifluoromethyl)pyrido[4,3-d]pyrimidin-4(3H)-one derivatives as orally -active calcium-sensing receptor antagonists. Bioorg. Med. Chem. Lett.19,4555–4559 (2009).▪ Structure–activity relationship study of the quinazolin-4-one series developed by Pfizer.
  Medline CASGoogle Scholar
• 58  Coombs RV, Danna RP, Denzer M et al. Synthesis and antiinflammatory activity of 1-alkyl-4-aryl-2(1H)-quinazolinones and quinazolinethiones. J. Med. Chem.16,1237–1245 (1973).
  Medline CASGoogle Scholar
• 59  Houlihan WJ, Cooke G, Van Bochoven R, Perrine J, Takesue EI, Jukniewicz EJ. Anti-inflammatory properties of 8-aryl-5-isopropyl-2H-1,3-dioxolo[4,5-g]quinazolin-6(5H)-ones and -thiones. J. Med. Chem.25,1110–1113 (1982).
  Medline CASGoogle Scholar
• 60  Perrine JW, Houlihan WJ, Takesue EI. Antiinflammatory and other pharmacodynamic properties of five members of the 4-aryl-1-isopropyl-2(1H)-quinazolinone series. Arzneimittelforschung34(8),879–885 (1984).
  Medline CASGoogle Scholar
• 61  Widler L, Altmann E, Beerli R et al. 1-alkyl-4-phenyl-6-alkoxy-1H-quinazoline-2-ones: a novel series of potent calcium-sensing receptor antagonists. J. Med. Chem.53,2250–2263 (2010).▪▪ Review paper on the discovery and development of the Novartis quinazolin-2-ones series.
  Medline CASGoogle Scholar
• 62  John M, Widler L, Gamse R et al. ATF936, a novel oral calcilytic, increases bone mineral density in rats and transiently releases parathyroid hormone in humans. Bone (In Press).
  Google Scholar
• 63  Widler L, Gamse R, Seuwen K et al. A novel calcium-sensing receptor antagonist leads to dose-dependent transient release of parathyroid hormone after oral administration to healthy volunteers – an initial proof-of-concept for a potential new class of anabolic osteoporosis therapeutics. J. Bone Miner. Res.23(Suppl. 49), (2008).
  Google Scholar
• 64  John M, Harfst E, Loeffler J et al. A 4-week study of AXT914, a novel calcilytic compound for oral bone anabolic osteoporosis therapy, in postmenopausal women. J. Bone Miner. Res.25(Suppl. 1),S332 (2010).
  Google Scholar
• 65  Gerspacher M, Altmann E, Beerli R et al. Penta-substituted benzimidazoles as potent antagonists of the calcium sensing receptor (CaSR-antagonists). Bioorg. Med. Chem. Lett.20,5161–5164 (2010).
  Medline CASGoogle Scholar
• 66  Petrel C, Kessler A, Mashlah F et al. Modeling and mutagenesis of the binding site of Calhex 231, a novel negative allosteric modulator of the extracellular Ca²⁺-sensing receptor. J. Biol. Chem.278,49487–49494 (2003).
  Medline CASGoogle Scholar
• 67  Petrel C, Kessler A, Dauban P, Dodd RH, Rogan D, Ruat M. Positive and negative allosteric modulators of the Ca²⁺-sensing receptor. J. Biol. Chem.279,18990–18997 (2004).
  Medline CASGoogle Scholar
• 68  Miedlich SU, Gama L, Seuwen K, Wolf RM, Breitwieser GE. Homology modeling of the transmembrane domain of the human calcium sensing receptor and localization of an allosteric binding site. J. Biol. Chem.279,7254–7263 (2004).
  Medline CASGoogle Scholar
• 69  Bu L, Michino M, Wolf RM, Brooks CL. Improved model building and assessment of the calcium-sensing receptor transmembrane domain. Proteins71,215–226 (2008).
  Medline CASGoogle Scholar
• 70  Hu J, Jiang J, Costanzi S et al. A missense mutation in the seven-transmembrane domain of the human Ca²⁺ receptor converts a negative allosteric modulator into a positive allosteric modulator. J. Biol. Chem.281,21558–21565 (2006).
  Medline CASGoogle Scholar
• 71  Magno AL, Ward BK, Ratajczak T. The calcium-sensing receptor: a molecular perspective. Endoc. Rev.32(1),3–30 (2010).
  MedlineGoogle Scholar
• 72  Brown EM. Clinical lessons from the calcium-sensing receptor. Nat.Rev. Endocrinol.3,122–133 (2007).
  CASGoogle Scholar
• 73  Tfelt-Hansen J, Brown EM. The calcium-sensing receptor in normal physiology and pathopyhsiology. Clin. Rev. Clin. Lab. Sci.42,35–70 (2005).
  Medline CASGoogle Scholar
• 74  Geibel JP, Hebert SC. The functions and roles of the extracellular Ca²⁺-sensing receptor along the gastrointestinal tract. Annu. Rev. Physiol.71,205–217 (2009).
  Medline CASGoogle Scholar
• 75  Ba J, Friedman PA. Calcium-sensing receptor regulation of renal mineral ion transport. Cell Calcium35,229–237 (2004).
  Medline CASGoogle Scholar
• 76  Weston AH, Absi M, Ward DT et al. Evidence in favor of a calcium-sensing receptor in arterial endothelial cells. Circ. Res.97,391–398 (2005).
  Medline CASGoogle Scholar
• 77  Chakravarti B, Dwivedi SKD, Mithal A, Chattopadhyay N. Calcium-sensing receptor in cancer: good cop or bad cop? Endocrine35,271–284 (2009).
  Medline CASGoogle Scholar
• 78  Rodland KD. The role of the calcium-sensing receptor in cancer. Cell Calcium35,291–295 (2004).
  Medline CASGoogle Scholar
• 79  Bandyopadhyay S, Tfelt-Hansen J, Chattopadhyay N. Diverse roles of extracellular calcium-sensing receptor in the central nervous system. J. Neurosci. Res.88,2073–2082 (2010).
  Medline CASGoogle Scholar
• 80  Brown EM. Familial hypocalciuric hypercalcemia and other disorders with resistance to extracellular calcium. Endocrinol. Metab. Clin. North Am.29,503–523 (2000).
  Medline CASGoogle Scholar
• 101  Smithkline Beecham Co. WO2010055631 (2009).
  Google Scholar
• 102  Japan Tobacco Inc. WO0214259 (2002).
  Google Scholar
• 103  Japan Tobacco Inc. WO2004094362 (2004).
  Google Scholar
• 104  Japan Tobacco Inc. WO2004106280 (2004).
  Google Scholar
• 105  Daiichi Sankyo Co. WO2010074089 (2010).
  Google Scholar
• 106  Asahi Kasai Pharma Corp. WO2009148052 (2009).
  Google Scholar
• 107  Novartis AG. WO2008107390 (2008).
  Google Scholar
• 108  Novartis AG WO2007020046 (2007).
  Google Scholar
• 201  De Lano WL. The PyMol Molecular Graphics System, Version 1.0r2. DeLano Scientific LLC. San Carlos, CA, USA. www.pymol.org
  Google Scholar